Curated from medtech publications. Product launches, FDA clearances, M&A, technology shifts — rewritten as short briefs, linked back to the source. Filter by theme below.
Edwards Lifesciences raised its full-year 2026 revenue growth guidance following solid second-quarter results, driven primarily by its transcatheter aortic valve replacement (TAVR) business, which generated $1.26 billion in Q2 revenues. The company's strong TAVR performance underpinned confidence in its revised outlook.
bioAffinity Technologies partnered with Pictor to develop and commercialize diagnostic tests for asthma and chronic obstructive pulmonary disease (COPD). The collaboration combines the companies' capabilities to advance respiratory disease diagnostics, though specific product timelines and technical details were not disclosed.
Arterex Tecate, a medical device contract manufacturer, opened a 9,000-square-foot ISO Class 8 clean room facility. The expansion increases manufacturing capacity for medical devices and demonstrates the company's investment in quality and regulatory compliance infrastructure.
TYBR Health secured $30 million in funding to expand market access for its B3 GEL orthopaedic hydrogel, which launched in the US in January 2026. The company plans to use the capital primarily to grow distribution and market penetration of the platform.
Nelipak Corporation, a healthcare packaging solutions provider, released its 2025 Sustainability Report detailing progress toward long-term sustainability goals and product innovations. The report aligns with the company's stated vision to support sustainable healthcare practices through packaging solutions.
Cardinal Health acquired Strive Medical and Adapt Health's diabetes unit in two deals totaling $360 million to expand its home care business. The acquisitions strengthen Cardinal Health's portfolio in at-home medical device and diabetes management services, supporting its stated growth strategy in the home care sector.
Tempus AI acquired Personalis for $1.5 billion in an all-stock deal focused on precision oncology. Personalis' minimal residual disease (MRD) testing platform will be integrated into Tempus' oncology portfolio, expanding the combined company's diagnostic and data capabilities in cancer care.
Tempus AI announced a $1.5 billion acquisition of Personalis, a liquid biopsy company specializing in minimal residual disease (MRD) assays that detect remaining cancer cells after treatment. Tempus has served as the commercial partner for Personalis's MRD test since 2023. The deal consolidates two players in the growing cancer diagnostics market.
Medline announced plans to open a 1-million-square-foot distribution facility in Perris, California, expanding its logistics network following a similar buildout in Texas. The facility is intended to increase capacity and operational flexibility for healthcare providers across the state.
The British Business Bank has committed €25 million to EQT Life Sciences' latest fund. The Bank has prior co-investment experience with EQT portfolio companies Phagenesis and Cyted Health, signaling continued backing of the venture capital firm's life-sciences investments.
RapidPulse secured $48 million in funding to advance clinical development of its aspiration technology for acute ischemic stroke treatment. The capital will support the company's efforts to move the system through clinical validation and toward market commercialization.
GE HealthCare and Catholic Health have formed a 10-year strategic alliance valued at approximately $500 million to expand precision diagnostics, advanced imaging, and AI-supported technology across Catholic Health's Long Island network. The partnership aims to increase access to diagnostic capabilities and modernize imaging infrastructure within the health system.
DePuy Synthes acquired Expanding Innovations, gaining access to the company's interbody cage systems for complex spinal surgery. The deal expands DePuy Synthes' spine portfolio.
Neko Health secured $700 million in funding as the Swedish health-screening company prepares to enter the US market with its first location in New York this year, followed by additional US sites. The funding round supports the company's expansion beyond its existing Scandinavian operations into the American medical-device and diagnostic-screening sector.
BIOTRONIK Neuro has acquired an intellectual property portfolio from Soin Neuroscience focused on spinal cord stimulation (SCS) technology. The deal expands BIOTRONIK's neuromodulation capabilities and IP footprint in the SCS market.
Neko Health secured $700 million in Series C funding co-led by Lightspeed Venture Partners and O.G. Venture Partners to support US expansion. The round included participation from Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, and BDT & MSD. Neko operates diagnostic imaging and health-screening services, positioning itself as a vendor in the preventive diagnostics and mobile imaging space.
Johnson & Johnson raised its fiscal 2026 outlook following strong second-quarter results, with MedTech contributing $8.9 billion of the division's $25.3 billion in total Q2 revenues. Growth was driven in part by its cardiovascular portfolio, including the Shockwave IVL lithotripsy system.
Women's health companies attracted record equity funding in 2025 as investors increased capital allocation to the sector. The surge reflects growing recognition that closing gender health gaps could add over $1 trillion annually to the global economy by 2040, driving venture and growth capital toward female-focused medical device and diagnostic companies.
Think Surgical secured a debt facility of up to $65 million from Symbiotic Capital. The company's flagship product is TMINI, a handheld robotic system for total knee arthroplasty procedures. The financing will support the company's operations and growth.
Neuraptive Therapeutics has secured an exclusive licence from Washington University in St. Louis for a bioresorbable wireless electronic stimulation device designed for peripheral nerve repair. The deal grants Neuraptive rights to commercialize the technology, which represents a strategic licensing partnership in the neurology device space.
Vermon, a Tours, France-based ultrasound contract manufacturer, opened a new 30,000-square-foot TransducerWorks facility in Pennsylvania—four times larger than its predecessor and equipped with ISO 7 and ISO 8 cleanrooms and integrated machine shop—and acquired Modeleus, an OEM ultrasound subsystem specialist, to establish the Vermon Group platform.
Edwards Lifesciences was ordered to pay a $10 million penalty after a court found the company violated antitrust law requirements in its 2024 acquisition of JC Medical. The FTC enforcement action followed a ruling that Edwards failed to comply with merger conditions.
Axel Johnson Inc. has acquired Fort Wayne Metals and its parent company Fort Wayne Metals Research Products. The nitinol supplier, founded in 1970 and based in Fort Wayne, Indiana, will remain headquartered at its current location under new ownership. Financial terms were not disclosed.
En Carta Diagnostics closed €5 million ($6.18 million) in funding to expand its at-home molecular diagnostic solutions. The financing will support scaling of the company's testing platform for consumers and clinical applications.
Virax Biolabs signed an exclusive commercial supply agreement with Fosun Diagnostics to distribute its ImmuneSelect immune profiling product line. The deal covers research-use-only applications of the immune profiling platform.
Otsuka ICU Medical announced a $500 million investment to expand its US manufacturing capacity, including construction of a new facility and upgrades to its existing Austin, Texas site. The expansion reflects the company's commitment to domestic production and supply-chain resilience for its medical device portfolio.
IKS Health acquired TruBridge for $557 million, integrating the EHR and revenue-cycle management vendor into its AI-powered care platform. The deal marks IKS Health's third acquisition in 2026 and expands its footprint in rural-hospital IT services.
GE HealthCare and Mayo Clinic have announced a partnership to conduct a theranostics research study focused on radioligand therapy. The collaboration will evaluate how imaging and biomarker data can inform personalized treatment approaches using RLT, combining diagnostic insights with targeted therapeutic delivery.
Leo Cancer Care raised $65 million in funding for its Marie radiotherapy platform, an upright positioning system paired with CT imaging for proton therapy delivery. The system received FDA clearance in July 2025. The funding supports commercialization of the platform, which addresses workflow and patient positioning in radiation oncology.
ResMed sold MatrixCare, its software business, to private-equity firm Frazier Healthcare Partners for $490 million, less than a decade after acquiring it for $750 million. The divestment reflects ResMed's strategic pivot to concentrate on its core sleep and respiratory care device portfolio.
Ottobock acquired Fesia Technology to expand its neuro-orthotics offerings. The deal brings Fesia's portfolio of functional electrical stimulation (FES) products used in neurorehabilitation into Ottobock's product line, strengthening its position in the neurological rehabilitation device market.
VB Spine has signed a definitive agreement to acquire exclusive rights to Augmedics' CT-Fluoro technology for spine surgery applications. CT-Fluoro combines computed tomography and fluoroscopy imaging to guide surgical procedures. The acquisition expands VB Spine's intraoperative imaging portfolio for spinal intervention.
Alcon and RxSight announced a co-development partnership valued at up to $200 million to create a tunable presbyopia-correcting intraocular lens (PCIOL) for cataract patients. The collaboration combines Alcon's surgical expertise with RxSight's light-adjustable lens technology to deliver customizable vision correction after implantation.
Zydus Lifesciences and Apollo Hospitals signed a memorandum of understanding to expand access to Shield, a multi-cancer detection test, across Apollo's hospital network in India. The partnership aims to broaden availability of the cancer screening diagnostic in the Indian market.
Vivani Medical has entered a reverse-merger agreement with ClearOne, combining its brain-computer interface (BCI) business with ClearOne to create a publicly listed entity. Upon completion, the combined company will be renamed Cortigent Holdings and will trade on Nasdaq, providing Vivani's BCI technology with public market access.
Zimmer Biomet plans to hire 500 technical professionals over three years at a new tech center in Bengaluru, India. Positions include software engineering, product design, R&D, quality, regulatory, and finance roles. The expansion reflects the orthopedic and spine device maker's strategy to build engineering and innovation capacity in lower-cost markets.
Materna Medical closed a $5 million funding round to advance its women's health device portfolio. The capital will fund completion of a pivotal trial for its pelvic floor protection system during childbirth, alongside commercial expansion efforts.
Zimmer Biomet agreed to acquire Pacira BioSciences' iovera device, a drug-free pain management system, for up to $140 million. The transaction expands Zimmer Biomet's portfolio in the orthopedic and pain-relief device space.
M&M International, a New Jersey-based supplier of high-precision stainless steel tubing for medical devices, has acquired KC Tech. M&M, founded in 1993, manufactures 304, 316-grade, and 17-7 stainless steel small-diameter tubing and operates manufacturing facilities in South Korea. The deal consolidates two suppliers serving the medical device sector.
Bill Hawkins, retired Medtronic chair and CEO, has joined the board of Ketryx, a regulatory software platform for life sciences companies. Hawkins noted in a statement that medtech leaders are seeking ways to leverage AI to accelerate safe innovation, signaling growing industry interest in regulatory automation tools.
106 older market stories available.